NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that the company will report third quarter 2025 financial results and trial investigators will provide case studies from first-line pancreatic cancer patients treated in the company’s Phase 2a study of atebimetinib in combination with FOLFIRINOX, on Wednesday, November 12, 2025, after the close of market. Immuneering will host a conference call and webcast at 1:30 pm PT / 4:30 pm ET on the same day.
Individuals interested in listening to the live conference call may do so through this webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other locations and reference conference ID 7742025. A webcast replay will be available from the “Investors” section of the Company’s website here.
To access the replay, please register via the webcast link on the Events page. The webcast will be available for one year following the completion of the call.
About Immuneering
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.
Media Contact:
Carson Creehan
202-878-8330
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Laurence Watts
619-916-7620
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.35 |
| Daily Change: | -0.10 -1.55 |
| Daily Volume: | 2,655,421 |
| Market Cap: | US$401.570M |
November 12, 2025 September 24, 2025 September 16, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
